American Academy of Asthma, Allergy and Immunology (AAAAI)

BioCryst will attend the 2026 American Academy of Asthma, Allergy and Immunology (AAAAI) from Feb 27 – Mar 2, 2026.

Filter
  • Long-Term, Sustained, Robust Hereditary Angioedema Attack Suppression with Navenibart Administered Every 3 and 6 Months: ALPHA-SOLAR Interim Results
    AAAAI | 2026 | HAE
  • Navenibart Demonstrates Durable Efficacy and Tolerability Across Biological Sexes: Subgroup Analysis from the ALPHA-STAR Trial
    AAAAI | 2026 | HAE
  • Navenibart Delays Time to First Attack in Hereditary Angioedema: Results from ALPHA-STAR 
    AAAAI | 2026 | HAE
  • Real-World Attack Rate Reductions After Berotralstat Initiation Among Patients with Hereditary Angioedema with Normal C1-Inhibitor Stratified by Prior Long-Term Prophylaxis
    AAAAI | 2026 | HAE
  • Impact of Berotralstat on Hereditary Angioedema Attack Rates in Patients with C1-Inhibitor Deficiency: Real-World Evidence Stratified by Prior Long-Term Prophylaxis
    AAAAI | 2026 | HAE
  • Impact of Berotralstat on Healthcare Resource Utilization in Patients with Hereditary Angioedema\ with Normal C1-Inhibitor
    AAAAI | 2026 | HAE
  • Reductions in Healthcare Resource Utilization Among Patients with Hereditary Angioedema with C1-Inhibitor Deficiency Following the Initiation of Berotralstat
    AAAAI | 2026 | HAE
  • Medication Routines Among Patients With Hereditary Angioedema
    AAAAI | 2026 | HAE
  • Oral Berotralstat Reduces the Rate of Moderate and Severe Attacks and Percentage of Days with HAE Symptoms Over 48 Weeks in Children Aged 2 to Less Than 12 Years: Interim Data from APeX-P
    AAAAI | 2026 | HAE
  • Oral Berotralstat Reduces Hereditary Angioedema Attack Rates in Pediatric Patients Aged 2 to <12 Years Without Long-Term Prophylaxis During the 12-Week Standard of Care Period: Interim Data from the APeX-P Study
    WSAAI | 2026 | HAE
Load more >>